Overview

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the bioequivalence of HS632 and Omalizumab (Xolair®) in a single subcutaneous administration in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Treatments:
Antibodies, Monoclonal
Omalizumab